NASDAQ:SRRK - Scholar Rock Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Scholar Rock Holding Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.11 -1.79 (-12.88 %) (As of 03/31/2020 04:00 PM ET) Add Compare Today's Range$11.09Now: $12.11▼$14.1050-Day Range$13.08MA: $14.55▼$17.1452-Week Range$6.95Now: $12.11▼$23.35Volume209,188 shsAverage Volume94,319 shsMarket Capitalization$360.97 millionP/E RatioN/ADividend YieldN/ABeta-0.03 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of transforming growth factor beta-1 to treat cancers resistant to checkpoint blockade therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRK Previous Symbol CUSIPN/A CIKN/A Webhttp://www.scholarrock.com/ Phone857-259-3860Debt Debt-to-Equity Ratio0.04 Current Ratio5.64 Quick Ratio5.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.49 million Price / Sales17.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book3.19Profitability EPS (Most Recent Fiscal Year)($1.85) Net Income$-51,000,000.00 Net Margins-248.88% Return on Equity-44.24% Return on Assets-27.10%Miscellaneous Employees65 Outstanding Shares29,808,000Market Cap$360.97 million Next Earnings Date5/12/2020 (Estimated) OptionableNot Optionable Receive SRRK News and Ratings via Email Sign-up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SRRK Rates by TradingView Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions How has Scholar Rock's stock been impacted by COVID-19 (Coronavirus)? Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SRRK stock has decreased by 18.5% and is now trading at $12.11. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Scholar Rock? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Scholar Rock. When is Scholar Rock's next earnings date? Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Scholar Rock. How were Scholar Rock's earnings last quarter? Scholar Rock Holding Corp (NASDAQ:SRRK) posted its quarterly earnings results on Thursday, March, 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The business earned $7.57 million during the quarter, compared to the consensus estimate of $5.45 million. Scholar Rock had a negative return on equity of 44.24% and a negative net margin of 248.88%. View Scholar Rock's earnings history. What price target have analysts set for SRRK? 3 analysts have issued 1 year price objectives for Scholar Rock's shares. Their forecasts range from $27.00 to $35.00. On average, they anticipate Scholar Rock's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 156.0% from the stock's current price. View analysts' price targets for Scholar Rock. Has Scholar Rock been receiving favorable news coverage? News articles about SRRK stock have been trending positive on Tuesday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Scholar Rock earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutScholar Rock. Are investors shorting Scholar Rock? Scholar Rock saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,901,200 shares, an increase of 6.2% from the February 27th total of 1,790,000 shares. Based on an average daily trading volume, of 80,500 shares, the short-interest ratio is currently 23.6 days. Currently, 9.7% of the company's shares are short sold. View Scholar Rock's Current Options Chain. Who are some of Scholar Rock's key competitors? Some companies that are related to Scholar Rock include Cortexyme (CRTX), Regenxbio (RGNX), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Coherus Biosciences (CHRS), Editas Medicine (EDIT), I-Mab (BDTX), Beam Therapeutics (BEAM), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Oyster Point Pharma (OYST), Sangamo Therapeutics (SGMO), Orchard Therapeutics (ORTX) and Krystal Biotech (KRYS). What other stocks do shareholders of Scholar Rock own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Global Blood Therapeutics (GBT), Coherus Biosciences (CHRS), Exelixis (EXEL), Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Thermo Fisher Scientific (TMO), ACADIA Pharmaceuticals (ACAD) and Atara Biotherapeutics (ATRA). Who are Scholar Rock's key executives? Scholar Rock's management team includes the following people: Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 54)Mr. Yung H. Chyung, Chief Medical Officer (Age 43)Ms. Rhonda M. Chicko, Chief Financial Officer (Age 53)Mr. Alan J. Buckler, Chief Scientific Officer (Age 59)Ms. Catherine Hu, Exec. Director of Investor Relations & Corp. Communications When did Scholar Rock IPO? (SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Scholar Rock's stock symbol? Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK." How do I buy shares of Scholar Rock? Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Scholar Rock's stock price today? One share of SRRK stock can currently be purchased for approximately $12.11. How big of a company is Scholar Rock? Scholar Rock has a market capitalization of $360.97 million and generates $20.49 million in revenue each year. The company earns $-51,000,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Scholar Rock employs 65 workers across the globe. View additional information about Scholar Rock. What is Scholar Rock's official website? The official website for Scholar Rock is http://www.scholarrock.com/. How can I contact Scholar Rock? Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected] MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 111 (Vote Outperform)Underperform Votes: 131 (Vote Underperform)Total Votes: 242MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: How Do Tariffs Affect Trade Balances?
